Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
13.81 USD | 0.00% | -1.22% | -23.74% |
Business Summary
Number of employees: 158
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Novel Therapies
100.0
%
| 10 | 100.0 % | 2 | 100.0 % | -83.69% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 10 | 100.0 % | 2 | 100.0 % | -83.69% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Bernard Coulie
CEO | Chief Executive Officer | 58 | 16-01-31 |
- | - | ||
Keith Cummings
DFI | Director of Finance/CFO | 47 | 18-11-30 |
Chief Tech/Sci/R&D Officer | - | 21-01-03 | |
Eric Lefebvre
CTO | Chief Tech/Sci/R&D Officer | 60 | 18-04-30 |
Scott Turner
CTO | Chief Tech/Sci/R&D Officer | 53 | 21-06-30 |
Investor Relations Contact | - | 20-10-31 | |
Minnie Kuo
PRN | Corporate Officer/Principal | - | 23-09-13 |
Corporate Officer/Principal | - | - | |
Rik Derynck
PRN | Corporate Officer/Principal | - | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
David Pyott
BRD | Director/Board Member | 70 | 21-01-11 |
Suzanne Bruhn
BRD | Director/Board Member | 60 | 16-06-30 |
Gayle Crowell
BRD | Director/Board Member | 73 | 20-01-07 |
Ho Young Huh
CHM | Chairman | 54 | 17-11-30 |
Bernard Coulie
CEO | Chief Executive Officer | 58 | 16-01-31 |
Thomas McCourt
BRD | Director/Board Member | 66 | 23-03-05 |
Darren Cline
BRD | Director/Board Member | 59 | 23-03-05 |
John Curnutte
BRD | Director/Board Member | 72 | 17-07-31 |
Smital Shah
BRD | Director/Board Member | 48 | 19-03-13 |
Katharine Knobil
BRD | Director/Board Member | 60 | 22-09-13 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 60,325,832 | 56,458,990 ( 93.59 %) | 0 | 93.59 % |
Company contact information
Pliant Therapeutics, Inc.
260 Littlefield Avenue
94080, South San Francisco
+650 481 6770
http://www.pliantrx.comSector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-23.74% | 833M | |
+30.38% | 684B | |
+26.51% | 568B | |
-4.36% | 361B | |
+19.30% | 329B | |
+3.73% | 284B | |
+16.70% | 240B | |
+8.78% | 208B | |
-7.93% | 200B | |
+7.68% | 166B |
- Stock Market
- Equities
- PLRX Stock
- Company Pliant Therapeutics, Inc.